Replies to post #2380 on Zynerba Pharmaceuticals (ZYNE)

[dhbuzz]

Zygel is a clear gel formulation of CBD designed for transdermal administration The Food and Drug Administration (FDA) has granted Fast Track designation to Zygel (ZYN002; Zynerba), a cannabidiol gel for the treatment of behavioral symptoms associated with Fragile X syndrome (FXS).
CBD Gel Gets Fast Tracked for Behavioral Symptoms Associated ...
www.empr.com/home/news/drugs-in-the-pipeline/cbd-gel-gets-fast-tracked-for-behavioral-symptoms-associated-with-fragile-x-syndrome/

[dhbuzz]

So,with that time line in mind it looks like Zygell could go to market
in 2020 vs mid 2021 if phase 3 FX trial results are in line.